Trial Profile
A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Oedema Secondary to CRVO
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2019
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Sponsors Eyetech Pharmaceuticals
- 21 Jun 2014 New trial record
- 18 Jan 2007
- 24 Aug 2005